Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avenue Therapeutics Inc (NQ: ATXI )

4.700 USD -0.240 (-4.86%)
Official Closing Price Updated: 7:33 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Avenue Therapeutics Inc

Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
From GlobeNewswire News Releases
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
From GlobeNewswire News Releases
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
Company Anticipates NDA Resubmission in February 2021 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics, Inc. ("Avenue Therapeutics" or the "Company") (NASDAQ: ATXI). Such investors are advised to contact Robert S.... 
From PR Newswire
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
Management to Host Conference Call at 8:30 a.m. ET 
From GlobeNewswire News Releases
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
From GlobeNewswire News Releases
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
From GlobeNewswire News Releases
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020
From GlobeNewswire News Releases
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints 
From GlobeNewswire News Releases
Fortress Biotech Added to Russell 3000® Index
From GlobeNewswire News Releases
Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
From GlobeNewswire News Releases
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
From GlobeNewswire News Releases
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
From GlobeNewswire News Releases
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
From GlobeNewswire News Releases
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
From GlobeNewswire News Releases
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
From GlobeNewswire News Releases
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
From GlobeNewswire News Releases
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
From GlobeNewswire News Releases
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development
From GlobeNewswire News Releases
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting
From GlobeNewswire News Releases
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
From GlobeNewswire News Releases
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
From GlobeNewswire News Releases
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
Management to host a conference call today at 9 am EDT 
From GlobeNewswire News Releases
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
Safety study completed; Expect to report data from 2nd pivotal Phase 3 trial by the end of second quarter 2019 
From GlobeNewswire News Releases
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G.... 
From GlobeNewswire News Releases
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
-- Expects to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Abdominoplasty Surgery in mid-2019 -- 
From GlobeNewswire News Releases
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage closing of the Acquisition Agreement previously... 
From GlobeNewswire News Releases
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI)
Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit has been filed and it is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or the "Company") (NasdaqCM:... 
From GlobeNewswire News Releases
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
Topline data readout expected in mid-2019 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of... 
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.